In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer shake-up continues as Lockwood-Taylor joins

This article is powered by OTC Bulletin & The Rose Sheet

Executive Summary

Patrick Lockwood-Taylor – a former senior executive at Procter & Gamble (P&G) – has been named as Bayer Consumer Health’s regional president for North America. With immediate effect, he takes over from Natalie Bartner, who has held the role since 2015 when she joined from Sanofi (OTC bulletin, 25 September 2015, page 23).

You may also be interested in...



In Bayer North America Executive Moves, Consumer Chief Lockwood-Taylor Adds US Business Top Post

Lockwood-Taylor will start post on 1 August while continuing as North America consumer health chief. Also in North America, Dave Tomasi adds chief commercial officer post and Jeff Jarrett moves to chief marketing officer.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel